Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
Cardiovascular Research Institute, Wuhan University, Wuhan, China.
JAMA Cardiol. 2020 Jul 1;5(7):802-810. doi: 10.1001/jamacardio.2020.0950.
Coronavirus disease 2019 (COVID-19) has resulted in considerable morbidity and mortality worldwide since December 2019. However, information on cardiac injury in patients affected by COVID-19 is limited.
To explore the association between cardiac injury and mortality in patients with COVID-19.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted from January 20, 2020, to February 10, 2020, in a single center at Renmin Hospital of Wuhan University, Wuhan, China; the final date of follow-up was February 15, 2020. All consecutive inpatients with laboratory-confirmed COVID-19 were included in this study.
Clinical laboratory, radiological, and treatment data were collected and analyzed. Outcomes of patients with and without cardiac injury were compared. The association between cardiac injury and mortality was analyzed.
A total of 416 hospitalized patients with COVID-19 were included in the final analysis; the median age was 64 years (range, 21-95 years), and 211 (50.7%) were female. Common symptoms included fever (334 patients [80.3%]), cough (144 [34.6%]), and shortness of breath (117 [28.1%]). A total of 82 patients (19.7%) had cardiac injury, and compared with patients without cardiac injury, these patients were older (median [range] age, 74 [34-95] vs 60 [21-90] years; P < .001); had more comorbidities (eg, hypertension in 49 of 82 [59.8%] vs 78 of 334 [23.4%]; P < .001); had higher leukocyte counts (median [interquartile range (IQR)], 9400 [6900-13 800] vs 5500 [4200-7400] cells/μL) and levels of C-reactive protein (median [IQR], 10.2 [6.4-17.0] vs 3.7 [1.0-7.3] mg/dL), procalcitonin (median [IQR], 0.27 [0.10-1.22] vs 0.06 [0.03-0.10] ng/mL), creatinine kinase-myocardial band (median [IQR], 3.2 [1.8-6.2] vs 0.9 [0.6-1.3] ng/mL), myohemoglobin (median [IQR], 128 [68-305] vs 39 [27-65] μg/L), high-sensitivity troponin I (median [IQR], 0.19 [0.08-1.12] vs <0.006 [<0.006-0.009] μg/L), N-terminal pro-B-type natriuretic peptide (median [IQR], 1689 [698-3327] vs 139 [51-335] pg/mL), aspartate aminotransferase (median [IQR], 40 [27-60] vs 29 [21-40] U/L), and creatinine (median [IQR], 1.15 [0.72-1.92] vs 0.64 [0.54-0.78] mg/dL); and had a higher proportion of multiple mottling and ground-glass opacity in radiographic findings (53 of 82 patients [64.6%] vs 15 of 334 patients [4.5%]). Greater proportions of patients with cardiac injury required noninvasive mechanical ventilation (38 of 82 [46.3%] vs 13 of 334 [3.9%]; P < .001) or invasive mechanical ventilation (18 of 82 [22.0%] vs 14 of 334 [4.2%]; P < .001) than those without cardiac injury. Complications were more common in patients with cardiac injury than those without cardiac injury and included acute respiratory distress syndrome (48 of 82 [58.5%] vs 49 of 334 [14.7%]; P < .001), acute kidney injury (7 of 82 [8.5%] vs 1 of 334 [0.3%]; P < .001), electrolyte disturbances (13 of 82 [15.9%] vs 17 of 334 [5.1%]; P = .003), hypoproteinemia (11 of 82 [13.4%] vs 16 of 334 [4.8%]; P = .01), and coagulation disorders (6 of 82 [7.3%] vs 6 of 334 [1.8%]; P = .02). Patients with cardiac injury had higher mortality than those without cardiac injury (42 of 82 [51.2%] vs 15 of 334 [4.5%]; P < .001). In a Cox regression model, patients with vs those without cardiac injury were at a higher risk of death, both during the time from symptom onset (hazard ratio, 4.26 [95% CI, 1.92-9.49]) and from admission to end point (hazard ratio, 3.41 [95% CI, 1.62-7.16]).
Cardiac injury is a common condition among hospitalized patients with COVID-19 in Wuhan, China, and it is associated with higher risk of in-hospital mortality.
自 2019 年 12 月以来,2019 年冠状病毒病(COVID-19)已在全球造成相当多的发病率和死亡率。然而,关于 COVID-19 患者心脏损伤的信息有限。
探讨 COVID-19 患者心脏损伤与死亡率之间的关系。
设计、地点和参与者:本队列研究于 2020 年 1 月 20 日至 2 月 10 日在中国武汉的人民医院进行,最终随访日期为 2020 年 2 月 15 日。所有连续住院的 COVID-19 实验室确诊患者均纳入本研究。
收集并分析临床实验室、影像学和治疗数据。比较有和无心脏损伤患者的结局。分析心脏损伤与死亡率的关系。
最终分析了 416 例住院 COVID-19 患者;中位年龄为 64 岁(范围为 21-95 岁),211 例(50.7%)为女性。常见症状包括发热(334 例[80.3%])、咳嗽(144 例[34.6%])和呼吸急促(117 例[28.1%])。82 例(19.7%)患者有心脏损伤,与无心脏损伤的患者相比,这些患者年龄更大(中位[范围]年龄,74 [34-95]岁 vs 60 [21-90]岁;P<0.001);合并症更多(例如,高血压 49 例[59.8%] vs 334 例[23.4%];P<0.001);白细胞计数更高(中位数[四分位数间距(IQR)],9400[6900-13800] vs 5500[4200-7400]细胞/μL)和 C 反应蛋白水平(中位数[IQR],10.2[6.4-17.0] vs 3.7[1.0-7.3]mg/dL),降钙素原(中位数[IQR],0.27[0.10-1.22] vs 0.06[0.03-0.10]ng/mL),肌酸激酶同工酶-肌红蛋白(中位数[IQR],3.2[1.8-6.2] vs 0.9[0.6-1.3]ng/mL),高敏肌钙蛋白 I(中位数[IQR],0.19[0.08-1.12] vs <0.006 [<0.006-0.009]μg/L),N 末端脑利钠肽前体(中位数[IQR],1689[698-3327] vs 139[51-335]pg/mL),天门冬氨酸氨基转移酶(中位数[IQR],40[27-60] vs 29[21-40]U/L)和肌酐(中位数[IQR],1.15[0.72-1.92] vs 0.64[0.54-0.78]mg/dL);影像学检查结果中多发斑片状和磨玻璃影的比例更高(53 例[64.6%] vs 15 例[4.5%])。与无心脏损伤的患者相比,有更多的心脏损伤患者需要无创性机械通气(38 例[46.3%] vs 13 例[3.9%];P<0.001)或有创性机械通气(18 例[22.0%] vs 14 例[4.2%];P<0.001)。与无心脏损伤的患者相比,有心脏损伤的患者并发症更常见,包括急性呼吸窘迫综合征(48 例[58.5%] vs 49 例[14.7%];P<0.001)、急性肾损伤(7 例[8.5%] vs 1 例[0.3%];P<0.001)、电解质紊乱(13 例[15.9%] vs 17 例[5.1%];P=0.003)、低蛋白血症(11 例[13.4%] vs 16 例[4.8%];P=0.01)和凝血障碍(6 例[7.3%] vs 6 例[1.8%];P=0.02)。与无心脏损伤的患者相比,有心脏损伤的患者死亡率更高(42 例[51.2%] vs 15 例[4.5%];P<0.001)。在 Cox 回归模型中,与无心脏损伤的患者相比,有心脏损伤的患者死亡风险更高,无论是从症状出现(风险比,4.26[95%置信区间,1.92-9.49])还是从入院到终点(风险比,3.41[95%置信区间,1.62-7.16])。
心脏损伤是中国武汉住院 COVID-19 患者的常见情况,与住院死亡率升高相关。